{
  "bill_id": "FL2025000S1356",
  "source_url": "http://custom.statenet.com/public/resources.cgi?id=ID:bill:FL2025000S1356&cuiq=93d84396-c63b-526a-b152-38b7f79b4cfd&client_md=e4f6fea4-27b4-5d41-b7d3-766fe52569f0",
  "versions": [
    {
      "date": "02/26/2025",
      "label": "Prefiled",
      "url": "https://custom.statenet.com/public/resources.cgi?mode=show_text&id=ID:bill:FL2025000S1356&verid=FL2025000S1356_20250226_0_F&",
      "raw_html": "<html>\n<head>\n<title>Bill Resource</title>\n\n<!--   <link href=\"https://custom.statenet.com/network/Common/css/extregtext.css\" rel=\"stylesheet\" type=\"text/css\" />-->\n   <link href=\"https://custom.statenet.com/network/Common/css/xmltext-2.0.css\" rel=\"stylesheet\" type=\"text/css\" />\n   <link href=\"https://custom.statenet.com/network/Common/css/additional-text.css\" rel=\"stylesheet\" type=\"text/css\" />\n\n\t<style type=\"text/css\">\n<!--\n\ntd, body {\n     background-color: white;\n\tfont-family: Verdana, Arial, Helvetica, sans-serif;\n\tfont-size: 12px;\n}\n\n.resourceContainer {\n   border: 1px solid black;\n}\n-->\n</style>\n</head>\n<body>\n\n    <div style=\"width: 750px; margin: auto\">\n       <div style=\"font-size: .8em;margin-bottom: 10px\"><table width=\"100%\"><tr><td align=\"left\" style=\"font-size: .8em;\"><div>The following has special meaning:</div>\n<div><u class=\"amendmentInsertedText\">green underline denotes added text</u></div>\n<div><strike class=\"amendmentDeletedText\">red struck out text denotes deleted text</strike></div></td> <td align=\"right\"><a href=\"https://www.lexisnexis.com/statenet/\"><img alt=\"Powered by State Net\" src=\"https://custom.statenet.com/network/poweredby.gif\" /></a></td></tr></table></div><table id=\"text-identifier\"><tr><td class=\"key\">2025 FL S 1356</td> <td><table><tr><td class=\"label\">Author:</td> <td>Burton</td></tr> <tr><td class=\"label\">Version:</td> <td>Prefiled</td></tr> <tr><td class=\"label\">Version Date:</td> <td>02/26/2025</td></tr></table></td></tr></table><div class=\"documentBody\">\n  <a name=\"head_document_section\"></a><div class=\"head\">\n   <p class=\"indent\">\n    <b>Florida Senate</b> - <b>2025</b>\n   </p>\n   <p class=\"right\">\n    <b>SB 1356</b>\n   </p>\n   <p class=\"indent\">\n    <b>By </b>Senator Burton</p>\n  </div>\n  <a name=\"code_document_section\"></a><div class=\"code\">\n   <p class=\"center\">A bill to be entitled</p>\n   <p class=\"indent\">An act relating to the Florida Institute for Pediatric Rare Diseases; creating s. 1004.4210, F.S.; establishing the Florida Institute for Pediatric Rare Diseases within the Florida State University College of Medicine; providing the goals of the institute; requiring the institute to establish and administer the Sunshine Genetics Pilot Program for a specified period; providing the purpose of the pilot program; providing institute responsibilities and duties relating to the pilot program; providing requirements for participation in the pilot program and data collection in the pilot program; providing reporting requirements for the pilot program; establishing the Sunshine Genetics Consortium for specified purposes; requiring the consortium to be administered at the institute by a board; providing for the membership and terms of the board; providing reporting requirements for the consortium; providing appropriations; providing an effective date.</p>\n  </div>\n  <a name=\"text_document_section\"></a><div class=\"text\">\n   <span>\n    <p class=\"indent\">Be It Enacted by the Legislature of the State of Florida:</p>\n   </span>\n   <p class=\"indent\">Section 1. Section 1004.4210, Florida Statutes, is created to read:</p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">1004.4210 The Florida Institute for Pediatric Rare Diseases; the Sunshine Genetics Pilot Program; the Sunshine Genetics Consortium. --</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) The Florida Institute for Pediatric Rare Diseases is established within the Florida State University College of Medicine as a statewide resource for pediatric rare disease research and clinical care. The purpose of the institute is to improve the quality of life and health outcomes for children and families affected by rare diseases by advancing knowledge, diagnosis, and treatment of pediatric rare diseases through research, clinical care, education, and advocacy.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) The goals of the institute are to:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) Conduct research to better understand the causes, mechanisms, and potential treatments for pediatric rare diseases, including leveraging emerging research methods.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Develop advanced diagnostic and genetic screening tools and techniques to enable health care providers to identify rare diseases in newborns and children more rapidly, accurately, and economically.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) Provide comprehensive multidisciplinary clinical services and care for children with rare diseases. Such care may include patient, family, and caregiver support and resources to help navigate the challenges associated with these conditions, support groups, and patient advocacy.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(d) Educate and train health care professionals, including genetic counselors, pediatricians, scientists, and other specialists in the field of pediatric rare diseases.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(e) Establish collaborations with other research institutions, medical centers, and government agencies whenever deemed appropriate by the institute director and to share expertise, raise awareness, and promote a collective effort to tackle pediatric rare diseases.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3)(a) The institute shall establish and administer the Sunshine Genetics Pilot Program to be administered for a period of 3 years. The pilot program shall offer genetic testing to newborns in addition to the state&#39;s newborn screening program.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) The institute shall partner with qualified state universities, colleges, and health care service providers to implement the pilot program and deliver and analyze genetic testing results for the pilot program.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) The pilot program shall be an opt-in program and a parent of a newborn must provide parental consent to join the pilot program.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(d) Upon the completion of the genetic testing through the pilot program, all testing data and reports shall be delivered to the parent&#39;s health care provider.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(e) The institute shall:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">1. Conduct the pilot program in accordance with the requirements of s. 760.40.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">2. Maintain a secure database to store all pilot program data, including newborn testing data.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">3. Deidentify all patient data.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">4. Upon the approval of the board of the Sunshine Genetics Consortium created under subsection (4), enter into an agreement with the consortium to share deidentified patient data.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(f) Upon the completion of the pilot program, the institute shall provide a report to the Governor, the President of the Senate, and the Speaker of the House of Representatives.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4)(a) The Sunshine Genetics Consortium is established to create a network of clinical and academic research professionals, geneticists, and physicians from state universities and the state&#39;s children&#39;s hospitals to collaborate with leaders in the genetic industry and build and support a culture of collaborative research and the development of cutting-edge genetic and precision medicine in the state. The consortium shall:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">1. Integrate state-of-the-art genomic sequencing technologies.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">2. Create a biorepository network and database for ongoing and future research.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">3. Leverage advancements in artificial intelligence utilization in genomics.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">4. Develop educational opportunities for clinicians on genomic tools.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">5. Support the growth and education of geneticists to meet demand.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">6. Raise funds from nonprofits, private industry, and others to expand the pilot program under subsection (3).</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">7. Promote patient care to support families with children diagnosed with genetic disorders.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b)1. The consortium shall be administered at the institute by an oversight board and shall meet periodically.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">2. The oversight board for the consortium shall serve 2 year terms and consist of the following voting members:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">a. One member from the Florida State University to be appointed by the Dean of the College of Medicine.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">b. One member from the University of Florida to be appointed by the Dean of the College of Medicine.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">c. One member from the University of South Florida to be appointed by the Dean of the College of Medicine.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">d. One member from the University of Miami to be appointed by the Dean of the College of Medicine.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">e. One member appointed by the Governor.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">f. One member appointed by the President of the Senate.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">g. One member appointed by the Speaker of the House of Representatives.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">3. The board shall be responsible for the technical performance and financial management of the consortium.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) The consortium shall annually provide a report to the Governor, the President of the Senate, and the Speaker of the House of Representatives.</u>\n   </p>\n   <p class=\"indent\">Section 2. <u class=\"amendmentInsertedText\">For the 2025-2026 fiscal year, the sum of $5 million in recurring funds is appropriated from the General Revenue Fund to the Florida Institute for Pediatric Rare Diseases.</u>\n   </p>\n   <p class=\"indent\">Section 3. <u class=\"amendmentInsertedText\">For the 2025-2026 fiscal year, the sum of $20 million in nonrecurring funds is appropriated from the General Revenue Fund to the Florida Institute for Pediatric Rare Diseases to launch and execute whole genome sequencing at birthing centers.</u>\n   </p>\n   <effective_clause>\n    <p class=\"indent\">Section 4. This act shall take effect July 1, 2025.</p>\n   </effective_clause>\n  </div>\n </div>\n    </div>\t\n<table cellpadding=0 cellspacing=0 width=\"100%\">\n   <tr>\n      <td>\n          Copyright &copy; 2025 State Net\n      </td>\n<BR>\n<!--???MOVED INTO resources.cgi      <td align=\"right\">\n          <img src=\"https://custom.statenet.com/network/poweredby.gif\" alt=\"Powered by State Net\">\n      </td>-->\n\n    </tr>\n</table>\n</body></html>\n",
      "markdown": "The following has special meaning: _green underline denotes added text_ ~~red struck out text denotes deleted text~~ | [![Powered by State Net](https://custom.statenet.com/network/poweredby.gif)](https://www.lexisnexis.com/statenet/)  \n---|---  \n  \n2025 FL S 1356 | | Author: | Burton  \n---|---  \nVersion: | Prefiled  \nVersion Date: | 02/26/2025  \n  \n**Florida Senate** \\- **2025**\n\n**SB 1356**\n\n**By** Senator Burton\n\nA bill to be entitled\n\nAn act relating to the Florida Institute for Pediatric Rare Diseases; creating\ns. 1004.4210, F.S.; establishing the Florida Institute for Pediatric Rare\nDiseases within the Florida State University College of Medicine; providing\nthe goals of the institute; requiring the institute to establish and\nadminister the Sunshine Genetics Pilot Program for a specified period;\nproviding the purpose of the pilot program; providing institute\nresponsibilities and duties relating to the pilot program; providing\nrequirements for participation in the pilot program and data collection in the\npilot program; providing reporting requirements for the pilot program;\nestablishing the Sunshine Genetics Consortium for specified purposes;\nrequiring the consortium to be administered at the institute by a board;\nproviding for the membership and terms of the board; providing reporting\nrequirements for the consortium; providing appropriations; providing an\neffective date.\n\nBe It Enacted by the Legislature of the State of Florida:\n\nSection 1. Section 1004.4210, Florida Statutes, is created to read:\n\n_1004.4210 The Florida Institute for Pediatric Rare Diseases; the Sunshine\nGenetics Pilot Program; the Sunshine Genetics Consortium. --_\n\n_(1) The Florida Institute for Pediatric Rare Diseases is established within\nthe Florida State University College of Medicine as a statewide resource for\npediatric rare disease research and clinical care. The purpose of the\ninstitute is to improve the quality of life and health outcomes for children\nand families affected by rare diseases by advancing knowledge, diagnosis, and\ntreatment of pediatric rare diseases through research, clinical care,\neducation, and advocacy._\n\n_(2) The goals of the institute are to:_\n\n_(a) Conduct research to better understand the causes, mechanisms, and\npotential treatments for pediatric rare diseases, including leveraging\nemerging research methods._\n\n_(b) Develop advanced diagnostic and genetic screening tools and techniques to\nenable health care providers to identify rare diseases in newborns and\nchildren more rapidly, accurately, and economically._\n\n_(c) Provide comprehensive multidisciplinary clinical services and care for\nchildren with rare diseases. Such care may include patient, family, and\ncaregiver support and resources to help navigate the challenges associated\nwith these conditions, support groups, and patient advocacy._\n\n_(d) Educate and train health care professionals, including genetic\ncounselors, pediatricians, scientists, and other specialists in the field of\npediatric rare diseases._\n\n_(e) Establish collaborations with other research institutions, medical\ncenters, and government agencies whenever deemed appropriate by the institute\ndirector and to share expertise, raise awareness, and promote a collective\neffort to tackle pediatric rare diseases._\n\n_(3)(a) The institute shall establish and administer the Sunshine Genetics\nPilot Program to be administered for a period of 3 years. The pilot program\nshall offer genetic testing to newborns in addition to the state 's newborn\nscreening program._\n\n_(b) The institute shall partner with qualified state universities, colleges,\nand health care service providers to implement the pilot program and deliver\nand analyze genetic testing results for the pilot program._\n\n_(c) The pilot program shall be an opt-in program and a parent of a newborn\nmust provide parental consent to join the pilot program._\n\n_(d) Upon the completion of the genetic testing through the pilot program, all\ntesting data and reports shall be delivered to the parent 's health care\nprovider._\n\n_(e) The institute shall:_\n\n_1\\. Conduct the pilot program in accordance with the requirements of s.\n760.40._\n\n_2\\. Maintain a secure database to store all pilot program data, including\nnewborn testing data._\n\n_3\\. Deidentify all patient data._\n\n_4\\. Upon the approval of the board of the Sunshine Genetics Consortium\ncreated under subsection (4), enter into an agreement with the consortium to\nshare deidentified patient data._\n\n_(f) Upon the completion of the pilot program, the institute shall provide a\nreport to the Governor, the President of the Senate, and the Speaker of the\nHouse of Representatives._\n\n_(4)(a) The Sunshine Genetics Consortium is established to create a network of\nclinical and academic research professionals, geneticists, and physicians from\nstate universities and the state 's children's hospitals to collaborate with\nleaders in the genetic industry and build and support a culture of\ncollaborative research and the development of cutting-edge genetic and\nprecision medicine in the state. The consortium shall:_\n\n_1\\. Integrate state-of-the-art genomic sequencing technologies._\n\n_2\\. Create a biorepository network and database for ongoing and future\nresearch._\n\n_3\\. Leverage advancements in artificial intelligence utilization in\ngenomics._\n\n_4\\. Develop educational opportunities for clinicians on genomic tools._\n\n_5\\. Support the growth and education of geneticists to meet demand._\n\n_6\\. Raise funds from nonprofits, private industry, and others to expand the\npilot program under subsection (3)._\n\n_7\\. Promote patient care to support families with children diagnosed with\ngenetic disorders._\n\n_(b)1. The consortium shall be administered at the institute by an oversight\nboard and shall meet periodically._\n\n_2\\. The oversight board for the consortium shall serve 2 year terms and\nconsist of the following voting members:_\n\n_a. One member from the Florida State University to be appointed by the Dean\nof the College of Medicine._\n\n_b. One member from the University of Florida to be appointed by the Dean of\nthe College of Medicine._\n\n_c. One member from the University of South Florida to be appointed by the\nDean of the College of Medicine._\n\n_d. One member from the University of Miami to be appointed by the Dean of the\nCollege of Medicine._\n\n_e. One member appointed by the Governor._\n\n_f. One member appointed by the President of the Senate._\n\n_g. One member appointed by the Speaker of the House of Representatives._\n\n_3\\. The board shall be responsible for the technical performance and\nfinancial management of the consortium._\n\n_(c) The consortium shall annually provide a report to the Governor, the\nPresident of the Senate, and the Speaker of the House of Representatives._\n\nSection 2. _For the 2025-2026 fiscal year, the sum of $5 million in recurring\nfunds is appropriated from the General Revenue Fund to the Florida Institute\nfor Pediatric Rare Diseases._\n\nSection 3. _For the 2025-2026 fiscal year, the sum of $20 million in\nnonrecurring funds is appropriated from the General Revenue Fund to the\nFlorida Institute for Pediatric Rare Diseases to launch and execute whole\ngenome sequencing at birthing centers._\n\nSection 4. This act shall take effect July 1, 2025.\n\nCopyright (C) 2025 State Net  \n  \n---\n\n",
      "latest_version": false
    },
    {
      "date": "03/04/2025",
      "label": "Introduced",
      "url": "https://custom.statenet.com/public/resources.cgi?mode=show_text&id=ID:bill:FL2025000S1356&verid=FL2025000S1356_20250304_0_I&",
      "raw_html": "<html>\n<head>\n<title>Bill Resource</title>\n\n<!--   <link href=\"https://custom.statenet.com/network/Common/css/extregtext.css\" rel=\"stylesheet\" type=\"text/css\" />-->\n   <link href=\"https://custom.statenet.com/network/Common/css/xmltext-2.0.css\" rel=\"stylesheet\" type=\"text/css\" />\n   <link href=\"https://custom.statenet.com/network/Common/css/additional-text.css\" rel=\"stylesheet\" type=\"text/css\" />\n\n\t<style type=\"text/css\">\n<!--\n\ntd, body {\n     background-color: white;\n\tfont-family: Verdana, Arial, Helvetica, sans-serif;\n\tfont-size: 12px;\n}\n\n.resourceContainer {\n   border: 1px solid black;\n}\n-->\n</style>\n</head>\n<body>\n\n    <div style=\"width: 750px; margin: auto\">\n       <div style=\"font-size: .8em;margin-bottom: 10px\"><table width=\"100%\"><tr><td align=\"left\" style=\"font-size: .8em;\"><div>The following has special meaning:</div>\n<div><u class=\"amendmentInsertedText\">green underline denotes added text</u></div>\n<div><strike class=\"amendmentDeletedText\">red struck out text denotes deleted text</strike></div></td> <td align=\"right\"><a href=\"https://www.lexisnexis.com/statenet/\"><img alt=\"Powered by State Net\" src=\"https://custom.statenet.com/network/poweredby.gif\" /></a></td></tr></table></div><table id=\"text-identifier\"><tr><td class=\"key\">2025 FL S 1356</td> <td><table><tr><td class=\"label\">Author:</td> <td>Burton</td></tr> <tr><td class=\"label\">Version:</td> <td>Introduced</td></tr> <tr><td class=\"label\">Version Date:</td> <td>03/04/2025</td></tr></table></td></tr></table><div class=\"documentBody\">\n  <a name=\"head_document_section\"></a><div class=\"head\">\n   <p class=\"indent\">\n    <b>Florida Senate</b> - <b>2025</b>\n   </p>\n   <p class=\"right\">\n    <b>SB 1356</b>\n   </p>\n   <p class=\"indent\">\n    <b>By </b>Senator Burton</p>\n  </div>\n  <a name=\"code_document_section\"></a><div class=\"code\">\n   <p class=\"center\">A bill to be entitled</p>\n   <p class=\"indent\">An act relating to the Florida Institute for Pediatric Rare Diseases; creating s. 1004.4210, F.S.; establishing the Florida Institute for Pediatric Rare Diseases within the Florida State University College of Medicine; providing the goals of the institute; requiring the institute to establish and administer the Sunshine Genetics Pilot Program for a specified period; providing the purpose of the pilot program; providing institute responsibilities and duties relating to the pilot program; providing requirements for participation in the pilot program and data collection in the pilot program; providing reporting requirements for the pilot program; establishing the Sunshine Genetics Consortium for specified purposes; requiring the consortium to be administered at the institute by a board; providing for the membership and terms of the board; providing reporting requirements for the consortium; providing appropriations; providing an effective date.</p>\n  </div>\n  <a name=\"text_document_section\"></a><div class=\"text\">\n   <span>\n    <p class=\"indent\">Be It Enacted by the Legislature of the State of Florida:</p>\n   </span>\n   <p class=\"indent\">Section 1. Section 1004.4210, Florida Statutes, is created to read:</p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">1004.4210 The Florida Institute for Pediatric Rare Diseases; the Sunshine Genetics Pilot Program; the Sunshine Genetics Consortium. --</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) The Florida Institute for Pediatric Rare Diseases is established within the Florida State University College of Medicine as a statewide resource for pediatric rare disease research and clinical care. The purpose of the institute is to improve the quality of life and health outcomes for children and families affected by rare diseases by advancing knowledge, diagnosis, and treatment of pediatric rare diseases through research, clinical care, education, and advocacy.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) The goals of the institute are to:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) Conduct research to better understand the causes, mechanisms, and potential treatments for pediatric rare diseases, including leveraging emerging research methods.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Develop advanced diagnostic and genetic screening tools and techniques to enable health care providers to identify rare diseases in newborns and children more rapidly, accurately, and economically.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) Provide comprehensive multidisciplinary clinical services and care for children with rare diseases. Such care may include patient, family, and caregiver support and resources to help navigate the challenges associated with these conditions, support groups, and patient advocacy.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(d) Educate and train health care professionals, including genetic counselors, pediatricians, scientists, and other specialists in the field of pediatric rare diseases.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(e) Establish collaborations with other research institutions, medical centers, and government agencies whenever deemed appropriate by the institute director and to share expertise, raise awareness, and promote a collective effort to tackle pediatric rare diseases.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3)(a) The institute shall establish and administer the Sunshine Genetics Pilot Program to be administered for a period of 3 years. The pilot program shall offer genetic testing to newborns in addition to the state&#39;s newborn screening program.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) The institute shall partner with qualified state universities, colleges, and health care service providers to implement the pilot program and deliver and analyze genetic testing results for the pilot program.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) The pilot program shall be an opt-in program and a parent of a newborn must provide parental consent to join the pilot program.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(d) Upon the completion of the genetic testing through the pilot program, all testing data and reports shall be delivered to the parent&#39;s health care provider.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(e) The institute shall:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">1. Conduct the pilot program in accordance with the requirements of s. 760.40.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">2. Maintain a secure database to store all pilot program data, including newborn testing data.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">3. Deidentify all patient data.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">4. Upon the approval of the board of the Sunshine Genetics Consortium created under subsection (4), enter into an agreement with the consortium to share deidentified patient data.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(f) Upon the completion of the pilot program, the institute shall provide a report to the Governor, the President of the Senate, and the Speaker of the House of Representatives.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4)(a) The Sunshine Genetics Consortium is established to create a network of clinical and academic research professionals, geneticists, and physicians from state universities and the state&#39;s children&#39;s hospitals to collaborate with leaders in the genetic industry and build and support a culture of collaborative research and the development of cutting-edge genetic and precision medicine in the state. The consortium shall:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">1. Integrate state-of-the-art genomic sequencing technologies.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">2. Create a biorepository network and database for ongoing and future research.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">3. Leverage advancements in artificial intelligence utilization in genomics.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">4. Develop educational opportunities for clinicians on genomic tools.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">5. Support the growth and education of geneticists to meet demand.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">6. Raise funds from nonprofits, private industry, and others to expand the pilot program under subsection (3).</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">7. Promote patient care to support families with children diagnosed with genetic disorders.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b)1. The consortium shall be administered at the institute by an oversight board and shall meet periodically.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">2. The oversight board for the consortium shall serve 2 year terms and consist of the following voting members:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">a. One member from the Florida State University to be appointed by the Dean of the College of Medicine.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">b. One member from the University of Florida to be appointed by the Dean of the College of Medicine.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">c. One member from the University of South Florida to be appointed by the Dean of the College of Medicine.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">d. One member from the University of Miami to be appointed by the Dean of the College of Medicine.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">e. One member appointed by the Governor.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">f. One member appointed by the President of the Senate.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">g. One member appointed by the Speaker of the House of Representatives.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">3. The board shall be responsible for the technical performance and financial management of the consortium.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) The consortium shall annually provide a report to the Governor, the President of the Senate, and the Speaker of the House of Representatives.</u>\n   </p>\n   <p class=\"indent\">Section 2. <u class=\"amendmentInsertedText\">For the 2025-2026 fiscal year, the sum of $5 million in recurring funds is appropriated from the General Revenue Fund to the Florida Institute for Pediatric Rare Diseases.</u>\n   </p>\n   <p class=\"indent\">Section 3. <u class=\"amendmentInsertedText\">For the 2025-2026 fiscal year, the sum of $20 million in nonrecurring funds is appropriated from the General Revenue Fund to the Florida Institute for Pediatric Rare Diseases to launch and execute whole genome sequencing at birthing centers.</u>\n   </p>\n   <effective_clause>\n    <p class=\"indent\">Section 4. This act shall take effect July 1, 2025.</p>\n   </effective_clause>\n  </div>\n </div>\n    </div>\t\n<table cellpadding=0 cellspacing=0 width=\"100%\">\n   <tr>\n      <td>\n          Copyright &copy; 2025 State Net\n      </td>\n<BR>\n<!--???MOVED INTO resources.cgi      <td align=\"right\">\n          <img src=\"https://custom.statenet.com/network/poweredby.gif\" alt=\"Powered by State Net\">\n      </td>-->\n\n    </tr>\n</table>\n</body></html>\n",
      "markdown": "The following has special meaning: _green underline denotes added text_ ~~red struck out text denotes deleted text~~ | [![Powered by State Net](https://custom.statenet.com/network/poweredby.gif)](https://www.lexisnexis.com/statenet/)  \n---|---  \n  \n2025 FL S 1356 | | Author: | Burton  \n---|---  \nVersion: | Introduced  \nVersion Date: | 03/04/2025  \n  \n**Florida Senate** \\- **2025**\n\n**SB 1356**\n\n**By** Senator Burton\n\nA bill to be entitled\n\nAn act relating to the Florida Institute for Pediatric Rare Diseases; creating\ns. 1004.4210, F.S.; establishing the Florida Institute for Pediatric Rare\nDiseases within the Florida State University College of Medicine; providing\nthe goals of the institute; requiring the institute to establish and\nadminister the Sunshine Genetics Pilot Program for a specified period;\nproviding the purpose of the pilot program; providing institute\nresponsibilities and duties relating to the pilot program; providing\nrequirements for participation in the pilot program and data collection in the\npilot program; providing reporting requirements for the pilot program;\nestablishing the Sunshine Genetics Consortium for specified purposes;\nrequiring the consortium to be administered at the institute by a board;\nproviding for the membership and terms of the board; providing reporting\nrequirements for the consortium; providing appropriations; providing an\neffective date.\n\nBe It Enacted by the Legislature of the State of Florida:\n\nSection 1. Section 1004.4210, Florida Statutes, is created to read:\n\n_1004.4210 The Florida Institute for Pediatric Rare Diseases; the Sunshine\nGenetics Pilot Program; the Sunshine Genetics Consortium. --_\n\n_(1) The Florida Institute for Pediatric Rare Diseases is established within\nthe Florida State University College of Medicine as a statewide resource for\npediatric rare disease research and clinical care. The purpose of the\ninstitute is to improve the quality of life and health outcomes for children\nand families affected by rare diseases by advancing knowledge, diagnosis, and\ntreatment of pediatric rare diseases through research, clinical care,\neducation, and advocacy._\n\n_(2) The goals of the institute are to:_\n\n_(a) Conduct research to better understand the causes, mechanisms, and\npotential treatments for pediatric rare diseases, including leveraging\nemerging research methods._\n\n_(b) Develop advanced diagnostic and genetic screening tools and techniques to\nenable health care providers to identify rare diseases in newborns and\nchildren more rapidly, accurately, and economically._\n\n_(c) Provide comprehensive multidisciplinary clinical services and care for\nchildren with rare diseases. Such care may include patient, family, and\ncaregiver support and resources to help navigate the challenges associated\nwith these conditions, support groups, and patient advocacy._\n\n_(d) Educate and train health care professionals, including genetic\ncounselors, pediatricians, scientists, and other specialists in the field of\npediatric rare diseases._\n\n_(e) Establish collaborations with other research institutions, medical\ncenters, and government agencies whenever deemed appropriate by the institute\ndirector and to share expertise, raise awareness, and promote a collective\neffort to tackle pediatric rare diseases._\n\n_(3)(a) The institute shall establish and administer the Sunshine Genetics\nPilot Program to be administered for a period of 3 years. The pilot program\nshall offer genetic testing to newborns in addition to the state 's newborn\nscreening program._\n\n_(b) The institute shall partner with qualified state universities, colleges,\nand health care service providers to implement the pilot program and deliver\nand analyze genetic testing results for the pilot program._\n\n_(c) The pilot program shall be an opt-in program and a parent of a newborn\nmust provide parental consent to join the pilot program._\n\n_(d) Upon the completion of the genetic testing through the pilot program, all\ntesting data and reports shall be delivered to the parent 's health care\nprovider._\n\n_(e) The institute shall:_\n\n_1\\. Conduct the pilot program in accordance with the requirements of s.\n760.40._\n\n_2\\. Maintain a secure database to store all pilot program data, including\nnewborn testing data._\n\n_3\\. Deidentify all patient data._\n\n_4\\. Upon the approval of the board of the Sunshine Genetics Consortium\ncreated under subsection (4), enter into an agreement with the consortium to\nshare deidentified patient data._\n\n_(f) Upon the completion of the pilot program, the institute shall provide a\nreport to the Governor, the President of the Senate, and the Speaker of the\nHouse of Representatives._\n\n_(4)(a) The Sunshine Genetics Consortium is established to create a network of\nclinical and academic research professionals, geneticists, and physicians from\nstate universities and the state 's children's hospitals to collaborate with\nleaders in the genetic industry and build and support a culture of\ncollaborative research and the development of cutting-edge genetic and\nprecision medicine in the state. The consortium shall:_\n\n_1\\. Integrate state-of-the-art genomic sequencing technologies._\n\n_2\\. Create a biorepository network and database for ongoing and future\nresearch._\n\n_3\\. Leverage advancements in artificial intelligence utilization in\ngenomics._\n\n_4\\. Develop educational opportunities for clinicians on genomic tools._\n\n_5\\. Support the growth and education of geneticists to meet demand._\n\n_6\\. Raise funds from nonprofits, private industry, and others to expand the\npilot program under subsection (3)._\n\n_7\\. Promote patient care to support families with children diagnosed with\ngenetic disorders._\n\n_(b)1. The consortium shall be administered at the institute by an oversight\nboard and shall meet periodically._\n\n_2\\. The oversight board for the consortium shall serve 2 year terms and\nconsist of the following voting members:_\n\n_a. One member from the Florida State University to be appointed by the Dean\nof the College of Medicine._\n\n_b. One member from the University of Florida to be appointed by the Dean of\nthe College of Medicine._\n\n_c. One member from the University of South Florida to be appointed by the\nDean of the College of Medicine._\n\n_d. One member from the University of Miami to be appointed by the Dean of the\nCollege of Medicine._\n\n_e. One member appointed by the Governor._\n\n_f. One member appointed by the President of the Senate._\n\n_g. One member appointed by the Speaker of the House of Representatives._\n\n_3\\. The board shall be responsible for the technical performance and\nfinancial management of the consortium._\n\n_(c) The consortium shall annually provide a report to the Governor, the\nPresident of the Senate, and the Speaker of the House of Representatives._\n\nSection 2. _For the 2025-2026 fiscal year, the sum of $5 million in recurring\nfunds is appropriated from the General Revenue Fund to the Florida Institute\nfor Pediatric Rare Diseases._\n\nSection 3. _For the 2025-2026 fiscal year, the sum of $20 million in\nnonrecurring funds is appropriated from the General Revenue Fund to the\nFlorida Institute for Pediatric Rare Diseases to launch and execute whole\ngenome sequencing at birthing centers._\n\nSection 4. This act shall take effect July 1, 2025.\n\nCopyright (C) 2025 State Net  \n  \n---\n\n",
      "latest_version": false
    },
    {
      "date": "03/19/2025",
      "label": "Substituted",
      "url": "https://custom.statenet.com/public/resources.cgi?mode=show_text&id=ID:bill:FL2025000S1356&verid=FL2025000S1356_20250319_0_S&",
      "raw_html": "<html>\n<head>\n<title>Bill Resource</title>\n\n<!--   <link href=\"https://custom.statenet.com/network/Common/css/extregtext.css\" rel=\"stylesheet\" type=\"text/css\" />-->\n   <link href=\"https://custom.statenet.com/network/Common/css/xmltext-2.0.css\" rel=\"stylesheet\" type=\"text/css\" />\n   <link href=\"https://custom.statenet.com/network/Common/css/additional-text.css\" rel=\"stylesheet\" type=\"text/css\" />\n\n\t<style type=\"text/css\">\n<!--\n\ntd, body {\n     background-color: white;\n\tfont-family: Verdana, Arial, Helvetica, sans-serif;\n\tfont-size: 12px;\n}\n\n.resourceContainer {\n   border: 1px solid black;\n}\n-->\n</style>\n</head>\n<body>\n\n    <div style=\"width: 750px; margin: auto\">\n       <div style=\"font-size: .8em;margin-bottom: 10px\"><table width=\"100%\"><tr><td align=\"left\" style=\"font-size: .8em;\"><div>The following has special meaning:</div>\n<div><u class=\"amendmentInsertedText\">green underline denotes added text</u></div>\n<div><strike class=\"amendmentDeletedText\">red struck out text denotes deleted text</strike></div></td> <td align=\"right\"><a href=\"https://www.lexisnexis.com/statenet/\"><img alt=\"Powered by State Net\" src=\"https://custom.statenet.com/network/poweredby.gif\" /></a></td></tr></table></div><table id=\"text-identifier\"><tr><td class=\"key\">2025 FL S 1356</td> <td><table><tr><td class=\"label\">Author:</td> <td>Burton</td></tr> <tr><td class=\"label\">Version:</td> <td>Substituted</td></tr> <tr><td class=\"label\">Version Date:</td> <td>03/19/2025</td></tr></table></td></tr></table><div class=\"documentBody\">\n  <a name=\"head_document_section\"></a><div class=\"head\">\n   <p class=\"indent\">\n    <b>Florida Senate</b> - <b>2025</b>\n   </p>\n   <p class=\"right\">\n    <b>CS for SB 1356</b>\n   </p>\n   <p class=\"indent\">\n    <b>By </b>the Committee on Education Postsecondary; and Senator Burton</p>\n  </div>\n  <a name=\"code_document_section\"></a><div class=\"code\">\n   <p class=\"center\">A bill to be entitled</p>\n   <p class=\"indent\">An act relating to the Florida Institute for Pediatric Rare Diseases; creating s. 1004.4211, F.S.; establishing the Florida Institute for Pediatric Rare Diseases within the Florida State University College of Medicine; providing the goals of the institute; requiring the institute to establish and administer the Sunshine Genetics Pilot Program for a specified period; providing the purpose of the pilot program; providing institute responsibilities and duties relating to the pilot program; providing requirements for participation in the pilot program and data collection and release in the pilot program; defining the term &quot;health care practitioner&quot;; providing reporting requirements for the pilot program; establishing the Sunshine Genetics Consortium for specified purposes; requiring the consortium to be administered at the institute by an oversight board; providing for the membership and terms of the board; providing meeting and reporting requirements for the consortium; providing appropriations; providing an effective date.</p>\n  </div>\n  <a name=\"text_document_section\"></a><div class=\"text\">\n   <span>\n    <p class=\"indent\">Be It Enacted by the Legislature of the State of Florida:</p>\n   </span>\n   <p class=\"indent\">Section 1. Section 1004.4211, Florida Statutes, is created to read:</p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">1004.4211 The Florida Institute for Pediatric Rare Diseases; the Sunshine Genetics Pilot Program; the Sunshine Genetics Consortium. --</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) The Florida Institute for Pediatric Rare Diseases is established within the Florida State University College of Medicine as a statewide resource for pediatric rare disease research and clinical care. The purpose of the institute is to improve the quality of life and health outcomes for children and families affected by rare diseases by advancing knowledge, diagnosis, and treatment of pediatric rare diseases through research, clinical care, education, and advocacy.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) The goals of the institute are to:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) Conduct research to better understand the causes, mechanisms, and potential treatments for pediatric rare diseases, including leveraging emerging research methods.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Develop advanced diagnostic and genetic screening tools and techniques to enable health care providers to identify rare diseases in newborns and children more rapidly, accurately, and economically.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) Provide comprehensive multidisciplinary clinical services and care for children with rare diseases. Such care may include, but is not limited to, patient, family, and caregiver support and resources to help navigate the challenges associated with these conditions, support groups, and patient advocacy.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(d) Educate and train health care professionals, including, but not limited to, genetic counselors, pediatricians, scientists, and other specialists in the field of pediatric rare diseases.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(e) Establish collaborations with other research institutions, medical centers, patient and family advocacy organizations, and government agencies whenever deemed appropriate by the institute director to share expertise, raise awareness, and promote a collective effort to tackle pediatric rare diseases.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3)(a) The institute shall establish and administer the Sunshine Genetics Pilot Program to be administered for a period of 5 years. The pilot program shall provide newborn genetic screening, including, but not limited to, whole genome sequencing. Genetic screening shall be performed by the institute and institutional members of the oversight board upon approval of the oversight board.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) The institute may establish partnerships with Florida universities and colleges and health care service providers to promote and assist in the implementation of the pilot program.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) The pilot program shall be an opt-in program and a parent of a newborn must provide consent to participate in the pilot program.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(d) The institute and institutional members of the oversight board shall release clinical findings of a newborn&#39;s screening to the newborn&#39;s health care practitioner and the newborn&#39;s parent. As used in this paragraph, the term &quot;health care practitioner&quot; means a physician or physician assistant licensed under chapter 458; an osteopathic physician or physician assistant licensed under chapter 459; an advanced practice registered nurse, registered nurse, or licensed practical nurse licensed under part I of chapter 464; a midwife licensed under chapter 467; a speech-language pathologist or audiologist licensed under part I of chapter 468; a dietitian or nutritionist licensed under part X of chapter 468; or a genetic counselor licensed under part III of chapter 483.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(e) The institute shall:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">1. Maintain a secure database to collect and store all pilot program data, including, but not limited to, newborn genomics sequence data and deidentified newborn data.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">2. Provide deidentified newborn data to members of the consortium pursuant to a data sharing agreement to support ongoing and future research.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(f) By December 1, 2030, the institute shall provide a report on the Sunshine Genetics Pilot Program to the Governor, the President of the Senate, and the Speaker of the House of Representatives. The report must include, at a minimum:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">1. Study population and enrollment metrics.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">2. Whole genome sequencing metrics.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">3. Clinical and public health impact.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">4. Cost effectiveness and economic benefits.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4)(a) The Sunshine Genetics Consortium is established to create a network of clinical and academic research professionals, geneticists, and physicians from state universities and the state&#39;s children&#39;s hospitals to collaborate with leaders in the genetic industry and build and support a culture of collaborative research and the development of cutting edge genetic and precision medicine in the state. The consortium shall:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">1. Integrate state-of-the-art genomic sequencing technologies.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">2. Advance research and the development of cutting edge genetic and precision medicine.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">3. Leverage advancements in artificial intelligence utilization in genomics.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">4. Develop educational opportunities for clinicians on genomic tools.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">5. Support the growth and education of geneticists to meet demand.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">6. Solicit and leverage funds from nonprofits, private industry, and others for the purpose of expanding the Sunshine Genetics Pilot Program and to support genetic screenings by institutional members of the oversight board.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">7. Promote patient care that supports families with children diagnosed with genetic disorders.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">8. Report on the use of deidentified newborn data by members of the consortium.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b)1. The consortium shall be administered at the institute by an oversight board. The board shall convene at least once every 6 months.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">2. The oversight board for the consortium shall consist of the director of the institute who shall serve as chair and the following voting members who shall serve 2-year terms:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">a. One member nominated by the dean of the University of Florida&#39;s College of Medicine and approved by the university&#39;s president.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">b. One member nominated by the dean of the University of South Florida&#39;s College of Medicine and approved by the university&#39;s president.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">c. One member nominated by the dean of the University of Miami&#39;s School of Medicine and approved by the university&#39;s president.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">d. One member appointed by the Governor.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">e. One member appointed by the President of the Senate.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">f. One member appointed by the Speaker of the House of Representatives.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">3. The board shall be responsible for the promotion and oversight of the consortium, including, but not limited to, the nomination and appointment of members of the consortium.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) Beginning October 15, 2026, and annually thereafter, the consortium shall provide a report to the Governor, the President of the Senate, and the Speaker of the House of Representatives on research projects, research findings, community outreach initiatives, and future plans for the consortium.</u>\n   </p>\n   <p class=\"indent\">Section 2. <u class=\"amendmentInsertedText\">For the 2025-2026 fiscal year, the sum of $5 million in recurring funds is appropriated from the General Revenue Fund to the Florida Institute for Pediatric Rare Diseases.</u>\n   </p>\n   <p class=\"indent\">Section 3. <u class=\"amendmentInsertedText\">For the 2025-2026 fiscal year, the sum of $20 million in nonrecurring funds is appropriated from the General Revenue Fund to the Florida Institute for Pediatric Rare Diseases for the implementation of the Sunshine Genetics Pilot Program established in s. 1004.4211, Florida Statutes.</u>\n   </p>\n   <effective_clause>\n    <p class=\"indent\">Section 4. This act shall take effect July 1, 2025.</p>\n   </effective_clause>\n  </div>\n </div>\n    </div>\t\n<table cellpadding=0 cellspacing=0 width=\"100%\">\n   <tr>\n      <td>\n          Copyright &copy; 2025 State Net\n      </td>\n<BR>\n<!--???MOVED INTO resources.cgi      <td align=\"right\">\n          <img src=\"https://custom.statenet.com/network/poweredby.gif\" alt=\"Powered by State Net\">\n      </td>-->\n\n    </tr>\n</table>\n</body></html>\n",
      "markdown": "The following has special meaning: _green underline denotes added text_ ~~red struck out text denotes deleted text~~ | [![Powered by State Net](https://custom.statenet.com/network/poweredby.gif)](https://www.lexisnexis.com/statenet/)  \n---|---  \n  \n2025 FL S 1356 | | Author: | Burton  \n---|---  \nVersion: | Substituted  \nVersion Date: | 03/19/2025  \n  \n**Florida Senate** \\- **2025**\n\n**CS for SB 1356**\n\n**By** the Committee on Education Postsecondary; and Senator Burton\n\nA bill to be entitled\n\nAn act relating to the Florida Institute for Pediatric Rare Diseases; creating\ns. 1004.4211, F.S.; establishing the Florida Institute for Pediatric Rare\nDiseases within the Florida State University College of Medicine; providing\nthe goals of the institute; requiring the institute to establish and\nadminister the Sunshine Genetics Pilot Program for a specified period;\nproviding the purpose of the pilot program; providing institute\nresponsibilities and duties relating to the pilot program; providing\nrequirements for participation in the pilot program and data collection and\nrelease in the pilot program; defining the term \"health care practitioner\";\nproviding reporting requirements for the pilot program; establishing the\nSunshine Genetics Consortium for specified purposes; requiring the consortium\nto be administered at the institute by an oversight board; providing for the\nmembership and terms of the board; providing meeting and reporting\nrequirements for the consortium; providing appropriations; providing an\neffective date.\n\nBe It Enacted by the Legislature of the State of Florida:\n\nSection 1. Section 1004.4211, Florida Statutes, is created to read:\n\n_1004.4211 The Florida Institute for Pediatric Rare Diseases; the Sunshine\nGenetics Pilot Program; the Sunshine Genetics Consortium. --_\n\n_(1) The Florida Institute for Pediatric Rare Diseases is established within\nthe Florida State University College of Medicine as a statewide resource for\npediatric rare disease research and clinical care. The purpose of the\ninstitute is to improve the quality of life and health outcomes for children\nand families affected by rare diseases by advancing knowledge, diagnosis, and\ntreatment of pediatric rare diseases through research, clinical care,\neducation, and advocacy._\n\n_(2) The goals of the institute are to:_\n\n_(a) Conduct research to better understand the causes, mechanisms, and\npotential treatments for pediatric rare diseases, including leveraging\nemerging research methods._\n\n_(b) Develop advanced diagnostic and genetic screening tools and techniques to\nenable health care providers to identify rare diseases in newborns and\nchildren more rapidly, accurately, and economically._\n\n_(c) Provide comprehensive multidisciplinary clinical services and care for\nchildren with rare diseases. Such care may include, but is not limited to,\npatient, family, and caregiver support and resources to help navigate the\nchallenges associated with these conditions, support groups, and patient\nadvocacy._\n\n_(d) Educate and train health care professionals, including, but not limited\nto, genetic counselors, pediatricians, scientists, and other specialists in\nthe field of pediatric rare diseases._\n\n_(e) Establish collaborations with other research institutions, medical\ncenters, patient and family advocacy organizations, and government agencies\nwhenever deemed appropriate by the institute director to share expertise,\nraise awareness, and promote a collective effort to tackle pediatric rare\ndiseases._\n\n_(3)(a) The institute shall establish and administer the Sunshine Genetics\nPilot Program to be administered for a period of 5 years. The pilot program\nshall provide newborn genetic screening, including, but not limited to, whole\ngenome sequencing. Genetic screening shall be performed by the institute and\ninstitutional members of the oversight board upon approval of the oversight\nboard._\n\n_(b) The institute may establish partnerships with Florida universities and\ncolleges and health care service providers to promote and assist in the\nimplementation of the pilot program._\n\n_(c) The pilot program shall be an opt-in program and a parent of a newborn\nmust provide consent to participate in the pilot program._\n\n_(d) The institute and institutional members of the oversight board shall\nrelease clinical findings of a newborn 's screening to the newborn's health\ncare practitioner and the newborn's parent. As used in this paragraph, the\nterm \"health care practitioner\" means a physician or physician assistant\nlicensed under chapter 458; an osteopathic physician or physician assistant\nlicensed under chapter 459; an advanced practice registered nurse, registered\nnurse, or licensed practical nurse licensed under part I of chapter 464; a\nmidwife licensed under chapter 467; a speech-language pathologist or\naudiologist licensed under part I of chapter 468; a dietitian or nutritionist\nlicensed under part X of chapter 468; or a genetic counselor licensed under\npart III of chapter 483._\n\n_(e) The institute shall:_\n\n_1\\. Maintain a secure database to collect and store all pilot program data,\nincluding, but not limited to, newborn genomics sequence data and deidentified\nnewborn data._\n\n_2\\. Provide deidentified newborn data to members of the consortium pursuant\nto a data sharing agreement to support ongoing and future research._\n\n_(f) By December 1, 2030, the institute shall provide a report on the Sunshine\nGenetics Pilot Program to the Governor, the President of the Senate, and the\nSpeaker of the House of Representatives. The report must include, at a\nminimum:_\n\n_1\\. Study population and enrollment metrics._\n\n_2\\. Whole genome sequencing metrics._\n\n_3\\. Clinical and public health impact._\n\n_4\\. Cost effectiveness and economic benefits._\n\n_(4)(a) The Sunshine Genetics Consortium is established to create a network of\nclinical and academic research professionals, geneticists, and physicians from\nstate universities and the state 's children's hospitals to collaborate with\nleaders in the genetic industry and build and support a culture of\ncollaborative research and the development of cutting edge genetic and\nprecision medicine in the state. The consortium shall:_\n\n_1\\. Integrate state-of-the-art genomic sequencing technologies._\n\n_2\\. Advance research and the development of cutting edge genetic and\nprecision medicine._\n\n_3\\. Leverage advancements in artificial intelligence utilization in\ngenomics._\n\n_4\\. Develop educational opportunities for clinicians on genomic tools._\n\n_5\\. Support the growth and education of geneticists to meet demand._\n\n_6\\. Solicit and leverage funds from nonprofits, private industry, and others\nfor the purpose of expanding the Sunshine Genetics Pilot Program and to\nsupport genetic screenings by institutional members of the oversight board._\n\n_7\\. Promote patient care that supports families with children diagnosed with\ngenetic disorders._\n\n_8\\. Report on the use of deidentified newborn data by members of the\nconsortium._\n\n_(b)1. The consortium shall be administered at the institute by an oversight\nboard. The board shall convene at least once every 6 months._\n\n_2\\. The oversight board for the consortium shall consist of the director of\nthe institute who shall serve as chair and the following voting members who\nshall serve 2-year terms:_\n\n_a. One member nominated by the dean of the University of Florida 's College\nof Medicine and approved by the university's president._\n\n_b. One member nominated by the dean of the University of South Florida 's\nCollege of Medicine and approved by the university's president._\n\n_c. One member nominated by the dean of the University of Miami 's School of\nMedicine and approved by the university's president._\n\n_d. One member appointed by the Governor._\n\n_e. One member appointed by the President of the Senate._\n\n_f. One member appointed by the Speaker of the House of Representatives._\n\n_3\\. The board shall be responsible for the promotion and oversight of the\nconsortium, including, but not limited to, the nomination and appointment of\nmembers of the consortium._\n\n_(c) Beginning October 15, 2026, and annually thereafter, the consortium shall\nprovide a report to the Governor, the President of the Senate, and the Speaker\nof the House of Representatives on research projects, research findings,\ncommunity outreach initiatives, and future plans for the consortium._\n\nSection 2. _For the 2025-2026 fiscal year, the sum of $5 million in recurring\nfunds is appropriated from the General Revenue Fund to the Florida Institute\nfor Pediatric Rare Diseases._\n\nSection 3. _For the 2025-2026 fiscal year, the sum of $20 million in\nnonrecurring funds is appropriated from the General Revenue Fund to the\nFlorida Institute for Pediatric Rare Diseases for the implementation of the\nSunshine Genetics Pilot Program established in s. 1004.4211, Florida\nStatutes._\n\nSection 4. This act shall take effect July 1, 2025.\n\nCopyright (C) 2025 State Net  \n  \n---\n\n",
      "latest_version": false
    },
    {
      "date": "04/03/2025",
      "label": "Substituted",
      "url": "https://custom.statenet.com/public/resources.cgi?mode=show_text&id=ID:bill:FL2025000S1356&verid=FL2025000S1356_20250403_0_S&",
      "raw_html": "<html>\n<head>\n<title>Bill Resource</title>\n\n<!--   <link href=\"https://custom.statenet.com/network/Common/css/extregtext.css\" rel=\"stylesheet\" type=\"text/css\" />-->\n   <link href=\"https://custom.statenet.com/network/Common/css/xmltext-2.0.css\" rel=\"stylesheet\" type=\"text/css\" />\n   <link href=\"https://custom.statenet.com/network/Common/css/additional-text.css\" rel=\"stylesheet\" type=\"text/css\" />\n\n\t<style type=\"text/css\">\n<!--\n\ntd, body {\n     background-color: white;\n\tfont-family: Verdana, Arial, Helvetica, sans-serif;\n\tfont-size: 12px;\n}\n\n.resourceContainer {\n   border: 1px solid black;\n}\n-->\n</style>\n</head>\n<body>\n\n    <div style=\"width: 750px; margin: auto\">\n       <div style=\"font-size: .8em;margin-bottom: 10px\"><table width=\"100%\"><tr><td align=\"left\" style=\"font-size: .8em;\"><div>The following has special meaning:</div>\n<div><u class=\"amendmentInsertedText\">green underline denotes added text</u></div>\n<div><strike class=\"amendmentDeletedText\">red struck out text denotes deleted text</strike></div></td> <td align=\"right\"><a href=\"https://www.lexisnexis.com/statenet/\"><img alt=\"Powered by State Net\" src=\"https://custom.statenet.com/network/poweredby.gif\" /></a></td></tr></table></div><table id=\"text-identifier\"><tr><td class=\"key\">2025 FL S 1356</td> <td><table><tr><td class=\"label\">Author:</td> <td>Burton</td></tr> <tr><td class=\"label\">Version:</td> <td>Substituted</td></tr> <tr><td class=\"label\">Version Date:</td> <td>04/03/2025</td></tr></table></td></tr></table><div class=\"documentBody\">\n  <a name=\"head_document_section\"></a><div class=\"head\">\n   <p class=\"indent\">\n    <b>Florida Senate</b> - <b>2025</b>\n   </p>\n   <p class=\"right\">\n    <b>CS for CS for SB 1356</b>\n   </p>\n   <p class=\"indent\">\n    <b>By </b>the Committees on Fiscal Policy; and Education Postsecondary; and Senators Burton and Berman</p>\n  </div>\n  <a name=\"code_document_section\"></a><div class=\"code\">\n   <p class=\"center\">A bill to be entitled</p>\n   <p class=\"indent\">An act relating to the Florida Institute for Pediatric Rare Diseases; creating s. 1004.4211, F.S.; establishing the Florida Institute for Pediatric Rare Diseases within the Florida State University College of Medicine; providing the purpose of the institute; providing the goals of the institute; requiring the institute to establish and administer the Sunshine Genetics Pilot Program for a specified period; providing the purpose of the pilot program; providing institute responsibilities and duties relating to the pilot program; providing requirements for participation in the pilot program and data collection and release in the pilot program; defining the term &quot;health care practitioner&quot;; providing reporting requirements for the pilot program; establishing the Sunshine Genetics Consortium for specified purposes; requiring the consortium to be administered at the institute by an oversight board; providing for the membership and terms of the board; providing reporting requirements for the consortium; specifying that implementation of the act is subject to appropriation; providing an effective date.</p>\n  </div>\n  <a name=\"text_document_section\"></a><div class=\"text\">\n   <span>\n    <p class=\"indent\">Be It Enacted by the Legislature of the State of Florida:</p>\n   </span>\n   <p class=\"indent\">Section 1. Section 1004.4211, Florida Statutes, is created to read:</p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">1004.4211 The Florida Institute for Pediatric Rare Diseases; the Sunshine Genetics Pilot Program; the Sunshine Genetics Consortium. --</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(1) The Florida Institute for Pediatric Rare Diseases is established within the Florida State University College of Medicine as a statewide resource for pediatric rare disease research and clinical care. The purpose of the institute is to improve the quality of life and health outcomes for children and families affected by rare diseases by advancing knowledge, diagnosis, and treatment of pediatric rare diseases through research, clinical care, education, and advocacy.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(2) The goals of the institute are to:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(a) Conduct research to better understand the causes, mechanisms, and potential treatments for pediatric rare diseases, including leveraging emerging research methods.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) Develop advanced diagnostic and genetic screening tools and techniques to enable health care providers to identify rare diseases in newborns and children more rapidly, accurately, and economically.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) Provide comprehensive multidisciplinary clinical services and care for children with rare diseases. Such care may include, but is not limited to, patient, family, and caregiver support and resources to help navigate the challenges associated with these conditions, support groups, and patient advocacy.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(d) Educate and train health care professionals, including, but not limited to, genetic counselors, pediatricians, scientists, and other specialists in the field of pediatric rare diseases.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(e) Establish collaborations with other research institutions, medical centers, patient and family advocacy organizations, and government agencies whenever deemed appropriate by the institute director to share expertise, raise awareness, and promote a collective effort to tackle pediatric rare diseases.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(3)(a) The institute shall establish and administer the Sunshine Genetics Pilot Program to be administered for a period of 5 years. The pilot program shall provide newborn genetic screening, including, but not limited to, whole genome sequencing. Genetic screening shall be performed by the institute and institutional members of the oversight board upon approval of the oversight board.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b) The institute may establish partnerships with Florida universities and colleges and health care service providers to promote and assist in the implementation of the pilot program.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) The pilot program shall be an opt-in program and a parent of a newborn must provide consent to participate in the pilot program.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(d) The institute and institutional members of the oversight board shall release clinical findings of a newborn&#39;s screening to the newborn&#39;s health care practitioner and the newborn&#39;s parent. As used in this paragraph, the term &quot;health care practitioner&quot; means a physician or physician assistant licensed under chapter 458; an osteopathic physician or physician assistant licensed under chapter 459; an advanced practice registered nurse, registered nurse, or licensed practical nurse licensed under part I of chapter 464; a midwife licensed under chapter 467; a speech-language pathologist or audiologist licensed under part I of chapter 468; a dietitian or nutritionist licensed under part X of chapter 468; or a genetic counselor licensed under part III of chapter 483.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(e) The institute shall:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">1. Maintain a secure database to collect and store all pilot program data, including, but not limited to, newborn genomics sequence data and deidentified newborn data.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">2. Provide deidentified newborn data to members of the consortium pursuant to a data sharing agreement to support ongoing and future research.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(f) By December 1, 2030, the institute shall provide a report on the Sunshine Genetics Pilot Program to the Governor, the President of the Senate, and the Speaker of the House of Representatives. The report must include, at a minimum:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">1. Study population and enrollment metrics.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">2. Whole genome sequencing metrics.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">3. Clinical and public health impact.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">4. Cost effectiveness and economic benefits.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(4)(a) The Sunshine Genetics Consortium is established to create a network of clinical and academic research professionals, geneticists, and physicians from state universities and this state&#39;s children&#39;s hospitals to collaborate with leaders in the genetics industry and build and support a culture of collaborative research and the development of cutting-edge genetic and precision medicine in the state. The consortium shall:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">1. Integrate state-of-the-art genomic sequencing technologies.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">2. Advance research and the development of cutting-edge genetic and precision medicine.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">3. Leverage advancements in artificial intelligence utilization in genomics.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">4. Develop educational opportunities for clinicians on genomic tools.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">5. Support the growth and education of geneticists to meet demand.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">6. Solicit and leverage funds from nonprofits, private industry, and others for the purpose of expanding the Sunshine Genetics Pilot Program and to support genetic screenings by institutional members of the oversight board.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">7. Promote patient care that supports families with children diagnosed with genetic disorders.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">8. Report on the use of deidentified newborn data by members of the consortium.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(b)1. The consortium shall be administered at the institute by an oversight board. The board shall convene at least once every 6 months.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">2. The oversight board for the consortium shall consist of the director of the institute, who shall serve as chair, and the following voting members, who shall serve 2-year terms:</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">a. One member nominated by the dean of the University of Florida&#39;s College of Medicine and approved by the university&#39;s president.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">b. One member nominated by the dean of the University of South Florida&#39;s College of Medicine and approved by the university&#39;s president.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">c. One member nominated by the dean of the University of Miami&#39;s School of Medicine and approved by the university&#39;s president.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">d. One member nominated by the dean of Florida International University&#39;s School of Medicine and approved by the university&#39;s president.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">e. One member nominated by Nicklaus Children&#39;s Hospital and approved by the hospital&#39;s president and chief executive officer.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">f. One member appointed by the Governor.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">g. One member appointed by the President of the Senate.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">h. One member appointed by the Speaker of the House of Representatives.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">3. The board shall be responsible for the promotion and oversight of the consortium, including, but not limited to, the nomination and appointment of members of the consortium.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(c) Beginning October 15, 2026, and annually thereafter, the consortium shall provide a report to the Governor, the President of the Senate, and the Speaker of the House of Representatives on research projects, research findings, community outreach initiatives, and future plans for the consortium.</u>\n   </p>\n   <p class=\"indent\">\n    <u class=\"amendmentInsertedText\">(5) The provisions of this section shall be implemented to the extent of available appropriations contained in the annual General Appropriations Act for such purpose.</u>\n   </p>\n   <effective_clause>\n    <p class=\"indent\">Section 2. This act shall take effect July 1, 2025.</p>\n   </effective_clause>\n  </div>\n </div>\n    </div>\t\n<table cellpadding=0 cellspacing=0 width=\"100%\">\n   <tr>\n      <td>\n          Copyright &copy; 2025 State Net\n      </td>\n<BR>\n<!--???MOVED INTO resources.cgi      <td align=\"right\">\n          <img src=\"https://custom.statenet.com/network/poweredby.gif\" alt=\"Powered by State Net\">\n      </td>-->\n\n    </tr>\n</table>\n</body></html>\n",
      "markdown": "The following has special meaning: _green underline denotes added text_ ~~red struck out text denotes deleted text~~ | [![Powered by State Net](https://custom.statenet.com/network/poweredby.gif)](https://www.lexisnexis.com/statenet/)  \n---|---  \n  \n2025 FL S 1356 | | Author: | Burton  \n---|---  \nVersion: | Substituted  \nVersion Date: | 04/03/2025  \n  \n**Florida Senate** \\- **2025**\n\n**CS for CS for SB 1356**\n\n**By** the Committees on Fiscal Policy; and Education Postsecondary; and\nSenators Burton and Berman\n\nA bill to be entitled\n\nAn act relating to the Florida Institute for Pediatric Rare Diseases; creating\ns. 1004.4211, F.S.; establishing the Florida Institute for Pediatric Rare\nDiseases within the Florida State University College of Medicine; providing\nthe purpose of the institute; providing the goals of the institute; requiring\nthe institute to establish and administer the Sunshine Genetics Pilot Program\nfor a specified period; providing the purpose of the pilot program; providing\ninstitute responsibilities and duties relating to the pilot program; providing\nrequirements for participation in the pilot program and data collection and\nrelease in the pilot program; defining the term \"health care practitioner\";\nproviding reporting requirements for the pilot program; establishing the\nSunshine Genetics Consortium for specified purposes; requiring the consortium\nto be administered at the institute by an oversight board; providing for the\nmembership and terms of the board; providing reporting requirements for the\nconsortium; specifying that implementation of the act is subject to\nappropriation; providing an effective date.\n\nBe It Enacted by the Legislature of the State of Florida:\n\nSection 1. Section 1004.4211, Florida Statutes, is created to read:\n\n_1004.4211 The Florida Institute for Pediatric Rare Diseases; the Sunshine\nGenetics Pilot Program; the Sunshine Genetics Consortium. --_\n\n_(1) The Florida Institute for Pediatric Rare Diseases is established within\nthe Florida State University College of Medicine as a statewide resource for\npediatric rare disease research and clinical care. The purpose of the\ninstitute is to improve the quality of life and health outcomes for children\nand families affected by rare diseases by advancing knowledge, diagnosis, and\ntreatment of pediatric rare diseases through research, clinical care,\neducation, and advocacy._\n\n_(2) The goals of the institute are to:_\n\n_(a) Conduct research to better understand the causes, mechanisms, and\npotential treatments for pediatric rare diseases, including leveraging\nemerging research methods._\n\n_(b) Develop advanced diagnostic and genetic screening tools and techniques to\nenable health care providers to identify rare diseases in newborns and\nchildren more rapidly, accurately, and economically._\n\n_(c) Provide comprehensive multidisciplinary clinical services and care for\nchildren with rare diseases. Such care may include, but is not limited to,\npatient, family, and caregiver support and resources to help navigate the\nchallenges associated with these conditions, support groups, and patient\nadvocacy._\n\n_(d) Educate and train health care professionals, including, but not limited\nto, genetic counselors, pediatricians, scientists, and other specialists in\nthe field of pediatric rare diseases._\n\n_(e) Establish collaborations with other research institutions, medical\ncenters, patient and family advocacy organizations, and government agencies\nwhenever deemed appropriate by the institute director to share expertise,\nraise awareness, and promote a collective effort to tackle pediatric rare\ndiseases._\n\n_(3)(a) The institute shall establish and administer the Sunshine Genetics\nPilot Program to be administered for a period of 5 years. The pilot program\nshall provide newborn genetic screening, including, but not limited to, whole\ngenome sequencing. Genetic screening shall be performed by the institute and\ninstitutional members of the oversight board upon approval of the oversight\nboard._\n\n_(b) The institute may establish partnerships with Florida universities and\ncolleges and health care service providers to promote and assist in the\nimplementation of the pilot program._\n\n_(c) The pilot program shall be an opt-in program and a parent of a newborn\nmust provide consent to participate in the pilot program._\n\n_(d) The institute and institutional members of the oversight board shall\nrelease clinical findings of a newborn 's screening to the newborn's health\ncare practitioner and the newborn's parent. As used in this paragraph, the\nterm \"health care practitioner\" means a physician or physician assistant\nlicensed under chapter 458; an osteopathic physician or physician assistant\nlicensed under chapter 459; an advanced practice registered nurse, registered\nnurse, or licensed practical nurse licensed under part I of chapter 464; a\nmidwife licensed under chapter 467; a speech-language pathologist or\naudiologist licensed under part I of chapter 468; a dietitian or nutritionist\nlicensed under part X of chapter 468; or a genetic counselor licensed under\npart III of chapter 483._\n\n_(e) The institute shall:_\n\n_1\\. Maintain a secure database to collect and store all pilot program data,\nincluding, but not limited to, newborn genomics sequence data and deidentified\nnewborn data._\n\n_2\\. Provide deidentified newborn data to members of the consortium pursuant\nto a data sharing agreement to support ongoing and future research._\n\n_(f) By December 1, 2030, the institute shall provide a report on the Sunshine\nGenetics Pilot Program to the Governor, the President of the Senate, and the\nSpeaker of the House of Representatives. The report must include, at a\nminimum:_\n\n_1\\. Study population and enrollment metrics._\n\n_2\\. Whole genome sequencing metrics._\n\n_3\\. Clinical and public health impact._\n\n_4\\. Cost effectiveness and economic benefits._\n\n_(4)(a) The Sunshine Genetics Consortium is established to create a network of\nclinical and academic research professionals, geneticists, and physicians from\nstate universities and this state 's children's hospitals to collaborate with\nleaders in the genetics industry and build and support a culture of\ncollaborative research and the development of cutting-edge genetic and\nprecision medicine in the state. The consortium shall:_\n\n_1\\. Integrate state-of-the-art genomic sequencing technologies._\n\n_2\\. Advance research and the development of cutting-edge genetic and\nprecision medicine._\n\n_3\\. Leverage advancements in artificial intelligence utilization in\ngenomics._\n\n_4\\. Develop educational opportunities for clinicians on genomic tools._\n\n_5\\. Support the growth and education of geneticists to meet demand._\n\n_6\\. Solicit and leverage funds from nonprofits, private industry, and others\nfor the purpose of expanding the Sunshine Genetics Pilot Program and to\nsupport genetic screenings by institutional members of the oversight board._\n\n_7\\. Promote patient care that supports families with children diagnosed with\ngenetic disorders._\n\n_8\\. Report on the use of deidentified newborn data by members of the\nconsortium._\n\n_(b)1. The consortium shall be administered at the institute by an oversight\nboard. The board shall convene at least once every 6 months._\n\n_2\\. The oversight board for the consortium shall consist of the director of\nthe institute, who shall serve as chair, and the following voting members, who\nshall serve 2-year terms:_\n\n_a. One member nominated by the dean of the University of Florida 's College\nof Medicine and approved by the university's president._\n\n_b. One member nominated by the dean of the University of South Florida 's\nCollege of Medicine and approved by the university's president._\n\n_c. One member nominated by the dean of the University of Miami 's School of\nMedicine and approved by the university's president._\n\n_d. One member nominated by the dean of Florida International University 's\nSchool of Medicine and approved by the university's president._\n\n_e. One member nominated by Nicklaus Children 's Hospital and approved by the\nhospital's president and chief executive officer._\n\n_f. One member appointed by the Governor._\n\n_g. One member appointed by the President of the Senate._\n\n_h. One member appointed by the Speaker of the House of Representatives._\n\n_3\\. The board shall be responsible for the promotion and oversight of the\nconsortium, including, but not limited to, the nomination and appointment of\nmembers of the consortium._\n\n_(c) Beginning October 15, 2026, and annually thereafter, the consortium shall\nprovide a report to the Governor, the President of the Senate, and the Speaker\nof the House of Representatives on research projects, research findings,\ncommunity outreach initiatives, and future plans for the consortium._\n\n_(5) The provisions of this section shall be implemented to the extent of\navailable appropriations contained in the annual General Appropriations Act\nfor such purpose._\n\nSection 2. This act shall take effect July 1, 2025.\n\nCopyright (C) 2025 State Net  \n  \n---\n\n",
      "latest_version": true
    }
  ]
}